Tiffanie McDowell
Areas of Focus
Overview
Tiffanie McDowell is a partner in Crowell & Moring's Orange County office, where she practices in the firm's Antitrust and Competition Group and Health Care groups. Her practice focuses primarily on complex antitrust litigation, pharmaceutical advertising, pricing and access issues, and health care recovery.
Career & Education
- University of Missouri, B.S., cum laude, political science, 2006
- University of Missouri, B.A., cum laude, international studies, 2006
- University of Missouri, B.B.A., cum laude, international business, 2006
- University of San Diego School of Law, J.D., Academic Scholarship, cum laude, 2012
- University of San Diego School of Law, LL.M., Dean's Academic Scholarship, cum laude, taxation, 2014
- California
Tiffanie's Insights
Client Alert | 2 min read | 02.25.25
Federal Court Limits Scope of California’s AB 824 Governing Reverse Payment Settlement Agreements
California’s Assembly Bill 824 (“AB 824”) was enacted in October 2019 to curb “reverse payment” settlements among pharmaceutical companies that are used to resolve or settle patent infringement claims. The law establishes a presumption that such settlement agreements, through which a brand-name manufacturer compensates a generic manufacturer to forego its patent challenges in exchange for an agreement to enter at a later date (but before the expiration of the branded company’s patents), are anticompetitive and unlawful. AB 824 imposes significant financial penalties, with violators facing civil fines of up to three times the value received from the agreement or $20 million, whichever is greater.
Client Alert | 3 min read | 12.24.24
Only Drugs Allowed: Federal Circuit Affirms Order To Delist Device Patents From the Orange Book
Client Alert | 2 min read | 06.27.24
Insights
Tripped at Customs: EU Seizures of Indian Generic Pharmaceutical Drugs in Transit
|08.19.15
Practitioner Treatise on International Business Vol. 2, Ralph Folsom ed.
Industries
Tiffanie's Insights
Client Alert | 2 min read | 02.25.25
Federal Court Limits Scope of California’s AB 824 Governing Reverse Payment Settlement Agreements
California’s Assembly Bill 824 (“AB 824”) was enacted in October 2019 to curb “reverse payment” settlements among pharmaceutical companies that are used to resolve or settle patent infringement claims. The law establishes a presumption that such settlement agreements, through which a brand-name manufacturer compensates a generic manufacturer to forego its patent challenges in exchange for an agreement to enter at a later date (but before the expiration of the branded company’s patents), are anticompetitive and unlawful. AB 824 imposes significant financial penalties, with violators facing civil fines of up to three times the value received from the agreement or $20 million, whichever is greater.
Client Alert | 3 min read | 12.24.24
Only Drugs Allowed: Federal Circuit Affirms Order To Delist Device Patents From the Orange Book
Client Alert | 2 min read | 06.27.24
